
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934**

For the Month of: March 2018

Commission File Number: 001-37847

MOTIF BIO PLC

(Exact name of registrant as specified in its charter)

125 Park Avenue

25th Floor

New York, New York 10011

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**MOTIF BIO PLC
FORM 6-K**

GRANT OF SHARE OPTIONS TO SENIOR MANAGEMENT

On March 1, 2018, Motif Bio plc (the “Company”) issued a regulatory news service announcement, a copy of which is attached as Exhibit 99.1 to this report on Form 6-K and incorporated by reference herein, announcing that the Company granted options to certain members of the Company’s senior management, under the Company’s 2015 share option plan, to purchase a total of 4,750,000 ordinary shares.

The information contained in this report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-222614 and 333-222042), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits

Exhibit 99.1 [Regulatory news service announcement issued by Motif Bio plc, dated March 1, 2018, entitled “Grant of share options to senior management”](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MOTIF BIO PLC

By: /s/ Graham Lumsden

Name: Graham Lumsden

Title: Chief Executive Officer

Date: March 1, 2018



1 March 2018

Motif Bio plc
 (“Motif Bio” or the “Company”)

Grant of share options to senior management

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 4,750,000 options to purchase ordinary shares of 1 pence each of Motif Bio (“Ordinary Shares”) under the Company’s 2015 share option plan. The options have an exercise price of 36.1 pence per Ordinary Share, being the closing price of the Ordinary Shares on February 28, 2018, the date of grant of the options.

Graham Lumsden, Chief Executive Officer, has been granted 3,000,000 options to purchase Ordinary Shares which vest over a four-year period, 2,000,000 of which are based on meeting certain performance targets. Jonathan Gold, Interim Chief Financial Officer, has been granted 1,000,000 options to purchase Ordinary Shares, 750,000 of which vest over a four-year period and are based on meeting certain performance targets and 250,000 of which will vest over a 12-month period beginning at the end of his interim assignment. Dr David Huang, Chief Medical Officer, was granted 750,000 options to purchase Ordinary Shares which vest over a four-year period.

For further information, please contact:

Motif Bio plc Graham Lumsden (Chief Executive Officer)	info@motifbio.com
Peel Hunt LLP (NOMAD & BROKER) Dr Christopher Golden Oliver Jackson	+ 44 (0)20 7418 8900
Northland Capital Partners Limited (BROKER) David Hignell/John Howes/Rob Rees	+44 (0)203 861 6625
Walbrook PR Ltd. (UK FINANCIAL PR & IR) Paul McManus/Helen Cresswell/ Lianne Cawthome	+44 (0) 20 7933 8780 motifbio@walbrookpr.com
MC Services AG (EUROPEAN IR) Raimund Gabriel	+49 (0)89 210 2280 raimund.gabriel@mc-services.eu
The Trout Group (US IR) Meggie Purcell	+ 1 (646) 378-2936 mpurcell@troutgroup.com
Russo Partners (US PR) David Schull Travis Kruse, Ph.D.	+1 (858) 717-2310 +1 (212) 845-4272 david.schull@russopartnersllc.com travis.kruse@russopartnersllc.com

1. Details of the person discharging managerial responsibilities / person closely associated

a. Name Graham Lumsden

2. Reason for the notification

a. Position/status Chief Executive Officer

b. Initial notification /Amendment Initial

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a. Name Motif Bio plc

b. LEI 54930080DN00QTIUUU84

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a. Description of the Financial instrument, type of instrument Identification code Options over ordinary shares of 1p each

GB00BVVT4H71

b. Nature of the transaction Grant of options to a PDMR

c. Price(s) and volume(s)	Price(s)	Volume(s)
	0p	3,000,000

d. Aggregated information N/A

- Aggregated volume
- Price

e. Date of the transaction 2018-02-28

f. Place of the transaction N/A

5. Details of the person discharging managerial responsibilities / person closely associated

a. Name Jonathan Gold

6. Reason for the notification

a. Position/status Interim Chief Financial Officer

b. Initial notification /Amendment Initial

7. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a. Name Motif Bio plc

b. LEI 54930080DN00QTIUUU84

8. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a. Description of the Financial instrument, type of instrument Identification code Options over ordinary shares of 1p each

GB00BVVT4H71

b.	Nature of the transaction	Grant of options to a PDMR	
c.	Price(s) and volume(s)	<u>Price(s)</u>	<u>Volume(s)</u>
		0p	1,000,000
d.	Aggregated information	N/A	
	<ul style="list-style-type: none"> • <i>Aggregated volume</i> • <i>Price</i> 		
e.	Date of the transaction	2018-02-28	
f.	Place of the transaction	N/A	

9. Details of the person discharging managerial responsibilities / person closely associated

a. Name Dr David Huang

10. Reason for the notification

a. Position/status Chief Medical Officer

b. Initial notification /Amendment Initial

11. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a. Name Motif Bio plc

b. LEI 54930080DN00QTIUUU84

12. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 1p each GB00BVVT4H71	
b.	Nature of the transaction	Grant of options to a PDMR	
c.	Price(s) and volume(s)	<u>Price(s)</u>	<u>Volume(s)</u>
		0p	750,000
d.	Aggregated information	N/A	
	<ul style="list-style-type: none"> • <i>Aggregated volume</i> • <i>Price</i> 		
e.	Date of the transaction	2018-02-28	
f.	Place of the transaction	N/A	